NurExone Biologic Reaches Key Milestone in Exosome Manufacturing

NurExone Biologic Inc., headquartered in Toronto and Haifa, Israel, has reported significant progress in their exosome manufacturing process. Exosomes, small vesicles released by cells, have shown considerable potential in regenerative medicine. NurExone’s flagship product, ExoPTEN, is being developed to treat acute spinal cord injuries and glaucoma using these exosomes.

In a recent study, NurExone aimed to confirm the consistency of their exosome production. They compared exosomes derived from bone marrow mesenchymal stem cells (MSCs) of two different donors. Despite the inherent variability in the stem cell materials, the exosome yields remained consistent in concentration and size distribution. This consistency underscores the reliability of NurExone's production techniques.

Dr. Noa Avni, the Director of Research and Development at NurExone, emphasized the importance of having a stable exosome production process to maintain product quality despite variations in stem cell sources. She noted that their proprietary technology enables large-scale production without genetic manipulation. This stability is critical for ensuring that the exosomes produced are of uniform quality every time.

Further tests were conducted to assess the effectiveness of these exosomes in targeting damaged tissues. Using an advanced animal model of spinal cord injury, exosomes from different donors were administered to rats with spinal cord compression injuries. These exosomes demonstrated strong and comparable abilities to home in on the injured areas, which is vital for their potential therapeutic use.

NurExone also explored various culture methods to produce exosomes, comparing traditional 2D culture conditions to their scalable 3D culture systems. The results indicated that exosomes produced by both methods had similar homing and targeting capabilities. However, the patented 3D culture system is expected to better support commercial mass production efforts, enhancing the scalability of their manufacturing process.

Dr. Lior Shaltiel, Chief Executive Officer of NurExone, highlighted the significance of these findings. He pointed out that ensuring the consistency of exosome production across different donors and culture systems, while maintaining their targeting abilities, is essential. This consistency will enable exosomes to serve as an efficient targeted system for drug delivery. He further noted that NurExone’s advancements in establishing a robust and scalable exosome manufacturing process pave the way for developing regenerative medicine treatments for various clinical conditions. These developments are expected to benefit both NurExone’s independent projects and future collaborations.

NurExone Biologic Inc. is a TSXV-listed pharmaceutical company developing exosome-based therapies for central nervous system injuries. Their leading product, ExoPTEN, has shown promise in preclinical studies by recovering motor function in 75% of treated laboratory rats through intranasal administration. ExoPTEN has been granted Orphan Drug Designation by the FDA. The company’s platform technology aims to offer innovative solutions for noninvasive targeted drug delivery for various indications.

NurExone’s advancements in exosome production demonstrate their commitment to developing reliable and scalable solutions in regenerative medicine. Their ability to maintain consistency across different production methods and raw materials positions them well for future clinical applications and potential collaborations with other drug companies.